-
- Muredach P. Reilly
- From the Cardiovascular Institute and Institute of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;
-
- Anand Rohatgi
- Division of Cardiology, University of Texas Southwestern Medical Center;
-
- Kimberly McMahon
- From the Cardiovascular Institute and Institute of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;
-
- Megan L. Wolfe
- From the Cardiovascular Institute and Institute of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;
-
- Shailesh C. Pinto
- From the Cardiovascular Institute and Institute of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;
-
- Thomas Rhodes
- Department of Epidemiology, Merck Research Laboratories, West Point, PA.
-
- Cynthia Girman
- Department of Epidemiology, Merck Research Laboratories, West Point, PA.
-
- Daniel J. Rader
- From the Cardiovascular Institute and Institute of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;
抄録
<jats:sec><jats:title>Background</jats:title><jats:p> Interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) integrate inflammatory and adipose signaling but also have direct vascular effects. We hypothesized that plasma levels of IL-6 and soluble tumor necrosis factor α receptor 2 (sol-TNFR2) would be related to coronary atherosclerosis beyond established risk factors and the metabolic syndrome. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> We examined the association of IL-6 and sol-TNFR2 with metabolic syndrome, C-reactive protein (CRP), and coronary artery calcification (CAC) in 875 asymptomatic participants in the Study of Inherited Risk of Coronary Atherosclerosis. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> IL-6 levels were 56% higher ( p < .001) and sol-TNFR2 levels 16% higher ( p < .001) in subjects with metabolic syndrome compared with those without. Both cytokines were associated with CAC beyond age, gender, Framingham risk scores, family history, metabolic syndrome, and CRP (odds ratio and 95% confidence interval of higher CAC for 1 SD increase in log-transformed cytokine levels: 1.23 [1.06-1.43], p = .006 for IL-6 and 1.15 [1.01-1.31], p = .04 for sol-TNFR2). In fact, cytokine levels were independently associated with CAC scores in the subgroup with metabolic syndrome and were additive to the homeostasis model assessment of insulin resistance in predicting CAC. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Plasma IL-6 and sol-TNFR2 levels were independently associated with CAC, suggesting a role in integrating innate immune and adipose signaling in promoting atherosclerosis and cardiovascular risk. Measurement of their levels may facilitate cardiovascular risk prediction and targeting of therapeutic strategies. </jats:p></jats:sec>
収録刊行物
-
- Journal of Investigative Medicine
-
Journal of Investigative Medicine 55 (1), 26-35, 2007-01
SAGE Publications